BDX Becton, Dickinson and Company

212.73USD+0.02%Mkt Cap: 57.93B USDP/E: 42.03

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laborat…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap57.93B USD
Enterprise Value73.66B USD
Revenue (TTM)19.46B USD
Gross Profit9.93B USD
Net Income (TTM)1.68B USD
Revenue/Share69.87 USD
Last Price212.73 USD
Fiscal Year EndSep 2026
MR QuarterSep 2026
Employees60.0K
CountryUS
SectorHealthcare
IndustryMedical Instruments & Supplies
ISIN—
Valuation
P/E (Trailing)42.03
P/E (Forward)14.95
PEG1.11
EV/EBITDA13.94
EV/Revenue3.79
P/S2.98
P/B2.35
EPS (TTM)5.06 USD
EPS (Forward)14.23 USD
52W Range
140.1191% of range220.35
52W High220.35 USD
52W Low140.11 USD
Profitability
Gross Margin45.44%
Oper. Margin15.67%
EBITDA Margin27.17%
Profit Margin7.68%
ROE6.61%
ROA3.03%
ROIC6.06%
ROCE6.35%
Growth
Revenue Growth-10.50%
Earnings Growth47.60%
Cash Flow & Leverage
Operating CF3.43B USD
CapEx (TTM)760.00M USD
FCF Margin21.29%
FCF Yield7.15%
Net Debt15.61B USD
Net Debt/EBITDA2.95
Net Debt/FCF3.77
Balance Sheet
Debt/Equity0.76
Current Ratio0.87
Quick Ratio0.37
Book Value/Sh90.43 USD
Cash/Share2.69 USD
Dividends
Fwd Div Rate4.24 USD
Trail. Div Rate0.00 USD
Div. Yield1.96%
5Y Avg Yield1.66%
Payout Ratio72.49%
Ex-Div DateDec 10, 2026
Pay DateDec 31, 2026
Splits
Last Split1272:1000
Split DateFeb 10, 2026
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)226.14 USD
Upside (mean)+6.3%
Target Range195.00 USD – 242.00 USD
195.00+6.3% to mean242.00
# Analysts14
Ownership
Shares Out.272.39M
Float272.21M
Insiders0.45%
Institutions98.49%
Short Interest
Short Ratio5.1d
Short % Float3.39%
Short % Out.2.98%
Shares Short8.11M
Short (prev mo.)9.78M
Technical
SMA 50193.02 (+10.2%)
SMA 200169.32 (+25.6%)
Beta0.28
S&P 52W Chg12.00%
Avg Vol (30d)1.81M
Avg Vol (10d)2.04M
Technical Indicators
RSI (14)62.9
MACD6.7263
MACD Signal6.8640
MACD Hist.-0.1377
BB Upper225.05 USD
BB Middle207.49 USD
BB Lower189.94 USD
BB Width16.92%
ATR (14)4.496 USD
Vol Ratio (20d)1.22x

About Becton, Dickinson and Company (NYSE: BDX)

›

Becton, Dickinson and Company (NYSE: BDX) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 60,000 employees.

The shares were at 212.73 USD on 19 November 2026, up 41.8% over 52 weeks. Its 52-week range is 140.11 USD to 220.35 USD: the price is 3.5% below the high and 51.8% above the low.

At a market capitalisation of 57.93B USD, it trades at 42.0 times trailing earnings and 15.0 times forward earnings. The median trailing P/E of its 18 largest Medical Instruments & Supplies peers is 51.8, a discount of 19% for BDX. It pays a dividend yielding 1.96% (it pays out 72% of its earnings), against a median of 0.71% among the dividend payers in that peer group.

Becton, Dickinson and Company reports return on equity of 6.6%, an operating margin of 15.7% and revenue down 10.5% year over year.

Its debt exceeds its cash by 15.61B USD, a debt-to-equity ratio of 0.76. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 226.14 USD is 6.3% above the current price. The next earnings report is expected on 9 February 2027.